Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Fabio P.S. Santos, Hagop M. Kantarjian, Nitin Jain, Taghi Manshouri, Deborah A. Thomas, Guillermo Garcia-Manero, Debra Kennedy, Zeev Estrov, Jorge Cortes, Srdan Verstovsek

Research output: Contribution to journal › Article › peer-review

194 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds